Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study

BACKGROUND: Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associated with reduced quality of life. Masitinib inhibits KIT and LYN kinases that are involved in indolent systemic mastocytosis pathogenesis. We aimed to assess safe...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet
Autori principali: Lortholary, Olivier, Chandesris, Marie Olivia, Livideanu, Cristina Bulai, Paul, Carle, Guillet, Gérard, Jassem, Ewa, Niedoszytko, Marek, Barete, Stéphane, Verstovsek, Srdan, Grattan, Clive, Damaj, Gandhi, Canioni, Danielle, Fraitag, Sylvie, Lhermitte, Ludovic, Lavialle, Sophie Georgin, Frenzel, Laurent, Afrin, Lawrence B, Hanssens, Katia, Agopian, Julie, Gaillard, Raphael, Kinet, Jean-Pierre, Auclair, Christian, Mansfield, Colin, Moussy, Alain, Dubreuil, Patrice, Hermine, Olivier
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5985971/
https://ncbi.nlm.nih.gov/pubmed/28069279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(16)31403-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi